|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:ATCCode
|
J05AB16
|
|
gptkbp:bioavailability
|
Not orally bioavailable
|
|
gptkbp:brand
|
gptkb:Veklury
|
|
gptkbp:CASNumber
|
1809249-37-3
|
|
gptkbp:contraindication
|
hypersensitivity to remdesivir
|
|
gptkbp:developer
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
antiviral drug
|
|
gptkbp:eliminationHalfLife
|
1 hour (plasma), 25 hours (metabolite)
|
|
gptkbp:form
|
solution for injection
lyophilized powder
|
|
gptkbp:hasAdministrationFrequency
|
once daily
|
|
gptkbp:hasBoxedWarning
|
nan
|
|
gptkbp:hasFirstApprovalCountry
|
gptkb:United_States
|
|
gptkbp:hasFirstApprovalDate
|
2020-10-22
|
|
gptkbp:hasInChIKey
|
RWWYLEGWBNMMLJ-YSOARWBDSA-N
|
|
gptkbp:hasMolecularFormula
|
C27H35N6O8P
|
|
gptkbp:hasPatentExpiry
|
2035
|
|
gptkbp:hasPatentHolder
|
gptkb:Gilead_Sciences
|
|
gptkbp:hasResearchUse
|
gptkb:Marburg_virus_disease
gptkb:Ebola_virus_disease
gptkb:MERS-CoV_infection
gptkb:SARS-CoV_infection
|
|
gptkbp:hasSMILES
|
CC(C)[C@@H](NC(=O)[C@@H](N)C(C)C)P(=O)(OCC1=CN(C2=NC=NC(=C21)N)C3CC3)OCC4=CC=CC=C4
|
|
gptkbp:hasStorageCondition
|
Store below 30°C
|
|
gptkbp:hasUNII
|
0N1J5A44B2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB13963
|
|
gptkbp:indication
|
gptkb:COVID-19
gptkb:Ebola_virus_infection_(investigational)
|
|
gptkbp:legalStatus
|
Prescription only
|
|
gptkbp:mechanismOfAction
|
RNA-dependent RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
Hepatic
|
|
gptkbp:molecularWeight
|
602.6 g/mol
|
|
gptkbp:name
|
gptkb:Remdesivir
|
|
gptkbp:pregnancyCategory
|
Not assigned
|
|
gptkbp:PubChem_CID
|
gptkb:DB13963
121304016
CHEMBL2016761
D11960
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
increased transaminases
|
|
gptkbp:status
|
FDA approved
|
|
gptkbp:synonym
|
gptkb:GS-5734
|
|
gptkbp:target
|
gptkb:viral_RNA_polymerase
|
|
gptkbp:therapeuticArea
|
gptkb:disease
|
|
gptkbp:bfsParent
|
gptkb:Axicabtagene_ciloleucel
gptkb:Lutathera
|
|
gptkbp:bfsLayer
|
7
|